Prime

Type your tag names separated by a space and hit enter

Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses.

Abstract

The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 microg/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40.1 +/- 13.3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH <or=2 mIU/l. Group S2 (n = 48, mean TPOAb = 803.9 +/- 483.8 IU/ml) received 200 microg L-selenomethionine per day, orally for 3 months, and group C (n = 40, mean TPOAb = 770.3 +/- 406.2 IU/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age- and TPOAb-matched groups. Group S22 (n = 20) went on taking L-selenomethionine 200 microg/day, while others (group S21) lowered the dose to 100 microg/day. (3) 12 patients of group S22 (group S222) went on taking L-selenomethionine 200 microg/day, while 12 patients of group S21 (S212) increased the dose to 200 microg/day. Serum titers of TPOAb decreased significantly in group S2 (26.2%, P < 0.001), group S22 (23.7%, P < 0.01) and group S212 (30.3%, P < 0.01). There were no significant changes in group C and group S222 (P > 0.05). TPOAb titers increased significantly in group S21 (38.1%, P < 0.01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5.2%, P < 0.01). L-selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 microg/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Thyroidology Unit, Department of Nuclear Medicine, GATA Haydarpasa, Istanbul, Turkey. otturker@yahoo.com

    , ,

    Source

    The Journal of endocrinology 190:1 2006 Jul pg 151-6

    MeSH

    Adult
    Analysis of Variance
    Antibodies, Monoclonal
    Drug Administration Schedule
    Female
    Follow-Up Studies
    Humans
    Iodide Peroxidase
    Male
    Middle Aged
    Selenium
    Statistics, Nonparametric
    Thyroiditis, Autoimmune
    Thyrotropin
    Thyroxine
    Triiodothyronine

    Pub Type(s)

    Comparative Study
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    16837619

    Citation

    TY - JOUR T1 - Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. AU - Turker,Omer, AU - Kumanlioglu,Kamil, AU - Karapolat,Inanc, AU - Dogan,Ismail, PY - 2006/7/14/pubmed PY - 2006/8/17/medline PY - 2006/7/14/entrez SP - 151 EP - 6 JF - The Journal of endocrinology JO - J. Endocrinol. VL - 190 IS - 1 N2 - The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 microg/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40.1 +/- 13.3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH <or=2 mIU/l. Group S2 (n = 48, mean TPOAb = 803.9 +/- 483.8 IU/ml) received 200 microg L-selenomethionine per day, orally for 3 months, and group C (n = 40, mean TPOAb = 770.3 +/- 406.2 IU/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age- and TPOAb-matched groups. Group S22 (n = 20) went on taking L-selenomethionine 200 microg/day, while others (group S21) lowered the dose to 100 microg/day. (3) 12 patients of group S22 (group S222) went on taking L-selenomethionine 200 microg/day, while 12 patients of group S21 (S212) increased the dose to 200 microg/day. Serum titers of TPOAb decreased significantly in group S2 (26.2%, P < 0.001), group S22 (23.7%, P < 0.01) and group S212 (30.3%, P < 0.01). There were no significant changes in group C and group S222 (P > 0.05). TPOAb titers increased significantly in group S21 (38.1%, P < 0.01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5.2%, P < 0.01). L-selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 microg/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time. SN - 0022-0795 UR - https://www.unboundmedicine.com/medline/citation/16837619/full_citation L2 - http://joe.endocrinology-journals.org/cgi/pmidlookup?view=long&amp;pmid=16837619 ER -